| 1.14 -0.04 (-3.39%) | 02-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.8  |
1-year : | 15.1 |
| Resists | First : | 8.39 |
Second : | 12.93 |
| Pivot price | 2.04 |
|||
| Supports | First : | 1.06 |
Second : | 0.88 |
| MAs | MA(5) : | 1.27 |
MA(20) : | 1.9 |
| MA(100) : | 2.01 |
MA(250) : | 2.44 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 0.9 |
D(3) : | 1.2 |
| RSI | RSI(14): 44.8 |
|||
| 52-week | High : | 14.5 | Low : | 1.06 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VERO ] has closed above bottom band by 37.2%. Bollinger Bands are 411.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.28 - 1.29 | 1.29 - 1.3 |
| Low: | 1.05 - 1.06 | 1.06 - 1.06 |
| Close: | 1.13 - 1.14 | 1.14 - 1.15 |
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
Tue, 03 Feb 2026
Venus Concept Updates Multiple Financing Agreements - TradingView
Thu, 29 Jan 2026
Is Venus Concept Inc Gaining or Losing Market Support? - Benzinga
Wed, 21 Jan 2026
Venus Concept Inc. Announces Voluntary Delisting from NASDAQ and Deregistration with SEC - Quiver Quantitative
Wed, 21 Jan 2026
Why Is Venus Concept Stock Plunging Today? - Sahm
Wed, 21 Jan 2026
Medical aesthetics firm Venus Concept quits Nasdaq to cut reporting costs - stocktitan.net
Wed, 21 Jan 2026
Venus Concept Announces Intention to Voluntary Delist from Nasdaq and Deregister with SEC - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 15.6 (%) |
| Shares Short | 173 (K) |
| Shares Short P.Month | 94 (K) |
| EPS | -45.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.44 |
| Profit Margin | -92.8 % |
| Operating Margin | -69 % |
| Return on Assets (ttm) | -32.5 % |
| Return on Equity (ttm) | -794.6 % |
| Qtrly Rev. Growth | -8.2 % |
| Gross Profit (p.s.) | 20.37 |
| Sales Per Share | 31.65 |
| EBITDA (p.s.) | -16.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.79 |
| Price to Sales | 0.03 |
| Price to Cash Flow | -0.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|